68 studies on PT-141 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This evaluation reinforces bremelanotide's role as an effective, on-demand pharmacological intervention for HSDD, offering a significant improvement in sexual desire and a reduction in distress for affected women. The…
This review consolidates extensive research, providing a clear roadmap for future drug development targeting the melanocortin system. The identification of potent and selective ligands for MC3R and MC4R offers novel a…
This review profoundly underscores the immense and expanding potential of the central melanocortin system as a drug target for a wide array of metabolic and behavioral disorders. The established safety profile and cli…
This comprehensive review provides a critical update on the management of HSDD in young women, highlighting the efficacy of both pharmacological and non-pharmacological treatments. It underscores the importance of a m…
These findings suggest that LibidoMax-P could represent a highly effective and well-tolerated therapeutic option for women suffering from HSDD, addressing a significant unmet medical need. The targeted LMR-1 agonism o…
This compelling case report offers a novel perspective on the therapeutic potential of flibanserin beyond its current indication for female HSDD. It suggests that drugs targeting serotonin pathways might be effective …
This review provides a critical and up-to-date summary of recent advancements, offering clinicians and researchers a valuable resource for understanding the evolving landscape of psychiatric pharmacotherapy. The intro…
This research highlights bremelanotide's potential as a novel therapeutic candidate for glioblastoma, a highly aggressive and treatment-resistant brain cancer. Given its known safety profile from other clinical applic…
This study highlights a critical gender bias in the management of sexual dysfunction within primary care, indicating that women may be systematically underserved. The findings underscore the urgent need for increased …
This research provides crucial insights into the neurobiological underpinnings of bremelanotide's action, specifically highlighting its impact on dopaminergic pathways in a relevant animal model. Understanding these m…
This comprehensive review is crucial for advancing clinical practice in managing female sexual dysfunction, a condition affecting a significant number of women. By consolidating information on both established and nov…
This innovative biodegradable suction patch represents a significant advancement in non-invasive drug delivery, particularly for peptide-based therapeutics. By offering sustained release and high bioavailability throu…
Understanding the genetic underpinnings of inflammatory diseases through MCR gene polymorphisms offers a crucial step towards personalized medicine. Identifying individuals with specific high-risk variants could enabl…
The clinical trials demonstrated significant improvements in key measures of sexual function and distress compared to placebo. In the pivotal trials, 25% of women treated with PT-141 reported a clinically meaningful i…
If successful, the findings from this Phase 3 trial could demonstrate that Bremelanotide offers a significant new treatment option for premenopausal women suffering from HSDD, a condition with substantial impact on qu…
The provided clinical trial registration record, which concluded in May 2007, confirms that the study successfully completed its 8-week duration as planned. However, specific efficacy and safety results, including det…